The MHC-II expression in tumors has been associated with increased formation of tertiary lymphoid structures, higher number of both CD4+ and CD8+ tumor-infiltrating lymphocytes, upregulation of genes associated with IFNγ pathway activation, absence of lymphovascular invasion, higher levels of IFNG, IL2, and IL12 mRNA, and improved survival including response to immune checkpoint inhibition, increased tumor-infiltrating lymphocytes, and proinflammatory IFN signaling in human tumors [63, 65]. The gene discussed is IL2; the disease is neoplasm.